Renal Denervation Market Trends

Rising cases of hypertension across people are driving the market growth

The rise in the spread of chronic diseases and the growing spread of hypertension is driving Market CAGR for renal denervation. One of the key drivers of market growth is the increase in occurrences of therapy-resistant hypertension. One of the most prevalent diseases in the world is hypertension. More than 360,000 Americans died in 2013 as a result of high blood pressure, according to the Centers for Disease Control and Prevention (CDC). From 17,307 per 100,000 people in 1990 to 20,525 per 100,000 people in 2015, hypertension has increased. However, renal denervation therapy has successfully decreased blood pressure.

The benefits of these therapies, such as their persistent effects, shorter treatment times, and improved safety levels, are thereby promoting market expansion. The development of renal denervation devices is also anticipated to fuel market growth.

As an illustration, the development of catheter-based interventional therapy to ablate the renal nerve has demonstrated excellent benefits in the management of blood pressure in patients presenting with complaints of resistant hypertension. Additionally, the catheter-based approach facilitates the denervation of particular nerves and seems to be safer for patients.

The amount of alcohol sold in 15 US states increased by 4% from January to August 2020 compared to a year earlier, as per the National Institute on Alcohol Abuse and Alcoholism. This could increase the risk of hypertension and encourage the use of renal denervation devices. Consequently, it is projected that the studied market would expand over the coming years as a result of factors such as an increase in product sales, the introduction of new products, and an increase in health problems connected to hypertension.

Growth in the market is also predicted to be fueled by an increase in clinical studies, research, and development related to renal denervation devices, as well as the long-term advantages of renal denervation treatments. For instance, according to research that appeared in April 2022 issue of the journal Nature, more than 80% of Thai patients with resistant hypertension benefited from the effectiveness of renal nerve denervation, which was maintained over a longer follow-up period without any intervention-related side effects.

It is also projected that the development of the healthcare infrastructure in emerging economies and the availability of substitutes and better technology, such as micro-infusion for renal denervation systems, will accelerate market expansion. For instance, the renal denervation system is based on micro-infusion from Mercator MedSystem. It distributes substances at a specified location to denervate the renal artery, lowering the patient’s blood pressure. Thus, driving the Renal Denervation Market revenue.

The Global Renal Denervation Market Industry is poised for substantial growth, with projections indicating a market size of 1.53 USD Billion in 2024 and an anticipated increase to 35.5 USD Billion by 2035. This remarkable growth trajectory suggests a compound annual growth rate of 33.1% from 2025 to 2035, highlighting the increasing demand for renal denervation procedures. Factors such as rising hypertension prevalence, technological advancements, and a supportive regulatory environment are likely to drive this growth. The market's expansion reflects a broader trend towards innovative solutions in managing chronic health conditions.

Increasing healthcare expenditure across various regions is positively impacting the Global Renal Denervation Market Industry. As governments and private sectors allocate more funds towards healthcare, there is a greater emphasis on innovative treatment options for chronic conditions such as hypertension. This trend is particularly evident in developed nations, where healthcare budgets are expanding to accommodate advanced medical technologies. The anticipated growth in healthcare spending is expected to facilitate the adoption of renal denervation procedures, contributing to the market's expansion and ensuring that patients have access to cutting-edge treatment options.

The increasing prevalence of hypertension globally serves as a primary driver for the Global Renal Denervation Market Industry. As hypertension affects approximately 1.13 billion people worldwide, the demand for effective treatment options is escalating. Renal denervation, a minimally invasive procedure, has emerged as a promising alternative for patients who do not respond to traditional antihypertensive medications. The market is projected to reach 1.53 USD Billion in 2024, reflecting the urgent need for innovative solutions to manage hypertension effectively. This trend is likely to continue as healthcare providers seek to address the growing burden of hypertension-related complications.

A supportive regulatory environment is fostering growth in the Global Renal Denervation Market Industry. Regulatory bodies are increasingly recognizing the potential of renal denervation as a treatment for hypertension, leading to expedited approvals for new devices and technologies. This regulatory support encourages manufacturers to invest in research and development, ultimately resulting in a wider array of treatment options for patients. As the market evolves, the favorable regulatory landscape is likely to enhance competition among manufacturers, driving innovation and improving patient access to renal denervation procedures.

Technological advancements in medical devices are significantly influencing the Global Renal Denervation Market Industry. Innovations such as improved catheter designs, enhanced imaging techniques, and robotic-assisted procedures are enhancing the efficacy and safety of renal denervation. These advancements not only improve patient outcomes but also increase the adoption rate among healthcare professionals. As a result, the market is expected to experience robust growth, with projections indicating a rise to 35.5 USD Billion by 2035. Such developments suggest that the integration of cutting-edge technology into renal denervation procedures could potentially revolutionize treatment paradigms.

Growing awareness and acceptance of renal denervation among both healthcare providers and patients are driving the Global Renal Denervation Market Industry. Educational initiatives and clinical trial results have contributed to a better understanding of the procedure's benefits, leading to increased patient referrals. As more patients become aware of renal denervation as a viable treatment option for resistant hypertension, the demand is likely to surge. This trend is expected to be reflected in the market's growth trajectory, with a compound annual growth rate of 33.1% projected from 2025 to 2035, indicating a shift towards more innovative hypertension management strategies.

Leading market players are investing largely in research & development-related activities to extend their product/service lines, which will aid the market of Renal Denervation, to grow faster. Market leaders are also adopting a range of strategies to expand their worldwide position, with important market developments including new product launches & developments, contractual agreements among companies with complementary service lines, mergers & acquisitions, increased investments, & collaboration with other organizations having complementary products and services. To grow in a competitive and rising market climate, the Renal Denervation industry needs to offer cost-efficient products.

Producing locally to cut operational expenses is one of the prime business strategies used by manufacturers in the Renal Denervation industry to benefit clients and increase the market sector. In recent years, the Renal Denervation industry has served with some of the key perks of medicine. Major players in the Renal Denervation Market, including Boston Scientific, Medtronic, ReCor Medical, St. Jude Medical, Cardiotonic, Cordis, Kona Medical, Sound Intervention, Terumo, and others are attempting to increase market growth via investing in research and development operations.

ReCor Medical is a manufacturer of medical equipment and a leader in the development of Ultrasound Renal Denervation (ADN) technology for the management of hypertension, one of the most common medical disorders. ReCor Medical creates and produces the Paradise Ultrasound Renal Denervation system, which uses ultrasound energy to treat overactive renal nerves during a single minimally invasive operation to control high blood pressure. Only exploratory use of the Paradise System is permitted within the United States. only for distribution in nations with CE certification. ReCor Medical Inc. is the owner of the trademark The Paradise System.

In February 2023, According to a study, the Paradise ultrasonic renal denervation (uRDN) device from ReCor Medical successfully lowered blood pressure. The Radiance clinical trial findings are significant because they confirm the Paradise uRDN System's usefulness as a supplementary therapy for the treatment of hypertension.

Designing, developing, producing, and marketing medical devices and solutions are the core competencies of Medtronic Plc (Medtronic), formerly known as Medtronic Inc. It provides goods for the treatment of conditions such as diseases of the heart valves, heart failure, peripheral vascular, venous renal, and neurological diseases, spine and musculoskeletal disorders, and ear, nose, and throat conditions. It also provides goods for the treatment of aortic, coronary, peripheral, and peripheral vascular diseases. For the dentistry and orthopedic businesses, it also offers biologic solutions.

In the regions of Asia Pacific, Europe, the Americas, the Middle East, and Africa, it offers its products to hospitals, third-party healthcare providers, clinics, institutions, and government healthcare programs. Dublin, Ireland serves as the company's headquarters. In September 2022, According to trial results released by Medtronic, the Symplicity renal denervation device significantly lowers blood pressure. The radiofrequency renal denervation (RF RDN) procedure was performed on individuals in the SYMPLICITY HTN-3 clinical trial using first-generation Symplicity. Results showed that when compared to a sham control group, office, and ambulatory blood pressure decreased statistically significantly.